NCT07095231View on ClinicalTrials.gov

Safety, Reactogenicity, and Immunogenicity Trial of STX-S SARS-CoV-2 Vaccine in Adults

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 11, 2025

Primary Completion Date

February 2, 2026

Study Completion Date

October 5, 2026

Conditions
COVID-19
Interventions
BIOLOGICAL

STX-S

A proprietary vaccine developed internally by Capricor utilizing exosomes that were engineered to express spike proteins on the surface

Trial Locations (3)

98104

RECRUITING

The University of Washington - Virology Research Clinic, Seattle

14642-0001

RECRUITING

University of Rochester Medical Center - Vaccine Research Unit, Rochester

98101-1466

RECRUITING

Kaiser Permanente Washington Health Research Institute, Seattle

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH